Published in Vaccines (Basel) on May 24, 2017
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making (2006) 3.50
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69
Indication-specific pricing for cancer drugs. JAMA (2014) 2.64
No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Clin Infect Dis (2015) 2.40
The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med (2012) 2.34
A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia. Clin Infect Dis (2014) 2.20
Contemporary costs of HIV healthcare in the HAART era. AIDS (2010) 2.16
A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making (2002) 2.12
Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition - United States, 2015. MMWR Morb Mortal Wkly Rep (2015) 2.05
Prevalence of Diagnosed and Undiagnosed HIV Infection--United States, 2008-2012. MMWR Morb Mortal Wkly Rep (2015) 1.99
The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med (2013) 1.98
Measuring the Value of Prescription Drugs. N Engl J Med (2015) 1.91
United States life tables, 2010. Natl Vital Stat Rep (2014) 1.84
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med (2012) 1.76
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care (2013) 1.66
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis (2015) 1.45
Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Curr Opin HIV AIDS (2012) 1.40
Estimating the Population Sizes of Men Who Have Sex With Men in US States and Counties Using Data From the American Community Survey. JMIR Public Health Surveill (2016) 1.24
Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr (2013) 1.19
The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine (2011) 1.06
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. J Acquir Immune Defic Syndr (2014) 1.05
A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health (2008) 1.04
Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine (2009) 1.01
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr (2014) 1.00
Costs, consequences and feasibility of strategies for achieving the goals of the National HIV/AIDS strategy in the United States: a closing window for success? AIDS Behav (2012) 0.93
Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.92
Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr (2013) 0.92
Modeling the impact of RV144-like vaccines on HIV transmission. Vaccine (2011) 0.91
Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. J Acquir Immune Defic Syndr (2009) 0.91
Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol (2015) 0.90
Untangling the cost-effectiveness knot: who is oral antiretroviral HIV pre-exposure prophylaxis really for? Expert Rev Pharmacoecon Outcomes Res (2014) 0.80
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. J Acquir Immune Defic Syndr (2013) 0.80
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med (2016) 0.80
Clinical correlation of the immunological markers of HIV infection in individuals from Thailand. AIDS (1992) 0.77
Large HIV Vaccine Trial Launches in South Africa. JAMA (2017) 0.77
The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review. Pharmacoeconom Open (2017) 0.75